Recently, the China stock market has undergone a sharp adjustment. The Shanghai Composite Index was adjusted from 5 170 to 3 100. Xinbang Pharmaceutical's share price has dropped from the previous peak of 26.65 yuan to the current 10.74 yuan. The adjustment is basically in place and there is not much room for decline. The next trend will be box sorting, and the overall trend will be a slow upward oscillation.
Introduction:
Xinbang Pharmaceutical is mainly engaged in the research, development, production and sales of pure natural plant Chinese patent medicines. At present, the main products focus on cardiovascular and cerebrovascular diseases and digestive system. There are 44 varieties with the national drug approval number and 24 varieties in the national medical insurance catalogue. IPO subscription of 20 10 Company began on the 6th, which is the first company listed in Guizhou in five years since Qianyuan Power entered the small and medium-sized board market in 2005.
20 10 On April 6th, Guizhou Xinbang Pharmaceutical Co., Ltd. began to apply for IPO, which is the first company listed in Guizhou in five years since Qianyuan Power entered the small and medium-sized board market in 2005.
Xinbang Pharmaceutical will issue 2,654.38+0.7 million shares to the public at the price of 33 yuan, with a price-earnings ratio of 63.46 times. After the successful issuance, it will raise 7 1665438+ 10,000 yuan, which is 52,065438+10,000 yuan more than the issuer intends to raise.